Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification

Y Li, G Nan, X Hou, Y Yan, Y Yang, Y Yang, K Li… - European Journal of …, 2023 - Elsevier
The immunoproteasome has emerged as a potential therapeutic target for idiopathic
pulmonary fibrosis (IPF). We report herein our efforts to discover novel non-peptidic …
相关文章

Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification

Y Li, G Nan, X Hou, Y Yan, Y Yang… - European journal of … - pubmed.ncbi.nlm.nih.gov
The immunoproteasome has emerged as a potential therapeutic target for idiopathic
pulmonary fibrosis (IPF). We report herein our efforts to discover novel non-peptidic …

Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification.

Y Li, G Nan, X Hou, Y Yan, Y Yang, K Li… - European Journal of …, 2023 - europepmc.org
The immunoproteasome has emerged as a potential therapeutic target for idiopathic
pulmonary fibrosis (IPF). We report herein our efforts to discover novel non-peptidic …